In vivo brain levels of acetylcholine and 5-hydroxytryptamine after oleoylethanolamide or palmitoylethanolamide administrations are mediated by PPARα engagement
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Not stated in the abstract (in vivo microdialysis study with systemic drug injection; species not specified)
- Dose used in the study
- Oleoylethanolamide (OEA) or PEA, 5, 10 or 30 mg/kg, injected intraperitoneally, with or without the PPAR-alpha antagonist MK-886 (30 mg/kg intraperitoneal)
- Duration
- Not stated in the abstract
- What was measured
- Acetylcholine and 5-hydroxytryptamine (serotonin) levels in the basal forebrain, using in vivo microdialysis and HPLC
What the authors reported
Both OEA and PEA significantly increased acetylcholine and 5-hydroxytryptamine levels in the basal forebrain. Pre-treatment with the PPAR-alpha antagonist MK-886 blocked these increases, indicating the effect depends on PPAR-alpha activation.
Limits of this study
An animal-model pharmacology study; it cannot show effect in people. Funding and conflicts not stated in the abstract.
Source
PubMed 34396611 · doi:10.1111/ejn.15409
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.